For high-dose oral solid dosage lines setting a target unit dose of 800 mg oxiracetam per tablet, direct compression is evaluated only after sieve and laser-diffraction data from the API certificate are compared against press-feed performance thresholds. A directly compressed monolayer core with a total mass of 1,000 mg places the API at 80.0 wt%; if the core mass is raised to 1,120 mg to accommodate a higher filler fraction, the API becomes 71.4 wt%. These ratios are arithmetic from the dose and total core mass, not extracted from a single marketing-authorization formula, because published commercial formulations for oxiracetam are not uniformly disclosed. The excipient set for such a high-load core is constrained to a flow-aid partition such as colloidal silicon dioxide at 0.25–0.75 wt%, disintegrant such as croscarmellose sodium at 1.0–3.0 wt%, and magnesium stearate at 0.25–0.75 wt%, with the remainder microcrystalline cellulose or a microcrystalline cellulose-lactose co-filler. Compatibility testing with the API must include forced degradation under ICH Q1B and accelerated stability per ICH Q1A; residual solvents should be controlled to ICH Q3C residual solvent classes, and elemental impurities must meet ICH Q3D optioned limits for an oral drug product. Blend uniformity is evaluated using USP <905> uniformity of dosage units on stratified samples from the blender, while powder flow is characterized by USP <1174> compressibility index and Hausner ratio. Development lots that show a flow function coefficient below 4 or a compressibility index above 20% typically show tablet weight variability exceeding ±3% at full press speed; under those conditions, dry granulation or wet granulation is required before compression. The compression process uses a rotary tablet press with precompression at 8–12 kN and main compression at 15–30 kN for a 19.0 × 9.0 mm caplet or 12.0 mm round tooling depending on core shape. Tablets are measured for breaking force under USP <1217>, friability under the harmonized pharmacopoeial chapter, disintegration under USP <701>, and dissolution under USP <711>. Terminal finished product types for this route are immediate-release film-coated tablets, biconvex uncoated tablets, or scored tablets; film coating is applied in a perforated pan to a weight gain of 2.0–3.0 wt% using an aqueous system after core porosity and hardness have been optimized to prevent edge erosion. Direct compression is not recommended for oxiracetam lots with a D50 below 50 µm or bulk density below 0.40 g/mL, because the high active fraction magnifies segregation and capping tendencies.

Why Wet Granulation Overrides Direct Compression in Capsule Filling of Brittle Oxiracetam API Lots

Capsule filling with oxiracetam at 400 mg per unit is often forced away from direct compression when the as-received API has a needle-like habit or a high fines fraction below 75 µm, because a dosator fill system requires low compressibility and consistent plug formation. In a wet-granulated formulation, the API can be brought to 78.4 wt% by placing 400 mg of oxiracetam in a total filled granule mass of 510 mg; if the formulation uses a higher proportion of starch dilution and binder, the same dose may fall to 64.5 wt% at 620 mg fill weight. These arithmetic ratios bracket the range that remains physically fillable in size 0 or size 00 hard capsules depending on tapped bulk density; if tapped bulk density is below 0.65 g/mL, a size 00 capsule may be required to avoid split fill weight. The wet granulation process uses a high-shear granulator or a low-shear planetary mixer; purified water or an aqueous binder solution containing povidone at 2.0–4.0 wt% of dry granule mass is added until the mass forms short, non-elastic agglomerates. The wet mass is dried in a fluid-bed drier at an inlet air temperature of 50–60°C to a loss-on-drying between 1.5% and 2.5%, then dry-milled through a 0.8 mm screen to narrow the granule fraction between 150 µm and 710 µm. Granule size is checked by Ph. Eur. 2.9.12 or USP <786> sieve analysis, and residual solvent is monitored under ICH Q3C. Before encapsulation, the granule blend is characterized by USP <1174> compressibility index and USP <905> dose uniformity on filled capsules; dissolution testing uses USP <711> with a defined aqueous or pH-specified medium that is fixed after stability data for the capsule shell type are reviewed. The finished product type is an immediate-release hard capsule filled with oxiracetam granules; both gelatin and HPMC capsule shells are acceptable only after shell cross-linking tests are excluded, because high-moisture granule residuals above 2.5% can induce gelatin-lid tack and supplier-specific shell brittleness. If a moisture-sensitive lot is combined with a hygroscopic diluent such as sorbitol, the LOD specification is tightened to 1.0–1.5% before filling; otherwise shell deformation and delayed disintegration may occur in accelerated storage conditions. It is not advisable to use lipid-based fill formulations for this water-soluble API because phase separation and precipitation at the capsule shell interface can occur, though published data for this specific configuration is limited.

Granule Sachet Fill Weight, Hygroscopicity, and the 1.5% LOD Boundary

Before sachet filling is run at full line speed, granule-density and loss-on-drying data are compared against auger feed calibration curves. A sachet containing 800 mg oxiracetam and a total granule fill of 1.00 g yields an API fraction of 80.0 wt%; a more dilute presentation with 400 mg in 750 mg total fill gives 53.3 wt%. The arithmetic ratios show that dose flexibility is achieved by adding soluble or mucoadhesive fillers such as mannitol, xylitol, or low-substituted hydroxypropyl cellulose, but each filler must be evaluated for dissolution suppression because oxiracetam is freely water-soluble and can dissolve rapidly during oral administration. Granulation for sachet use is performed by fluid-bed top-spray or high-shear wet granulation; the binder is typically povidone or hydroxypropyl methylcellulose at 1.5–3.0 wt% of dry granule mass. After drying to a loss-on-drying between 1.0% and 2.0%, the granules are milled and screened to retain 150–850 µm particles; the acceptable granule size distribution is verified using Ph. Eur. 2.9.12 or USP <786>. Sachet filling requires a powder flow characterized by a compressibility index below 15% and a Hausner ratio below 1.18 if the auger fill system has no forced gravimetric correction; otherwise the fill weight variability will exceed ±5% at high line speed. Moisture control is the central operational boundary: when packaging is performed above 40% relative humidity, hygroscopic fractions in mannitol or sorbitol can raise granule moisture above 2.5%, causing agglomeration and inconsistent screw feed. Packaging material must be a heat-sealable laminate such as polyethylene/aluminium/polyester with a moisture vapour transmission rate lower than 0.10 g/m²/day, and desiccant insertion should be considered only after stability data confirm that residual moisture remains within specification. Compliance for sachet granules includes USP <905> for unit-dose uniformity, ICH Q3D for elemental impurities, ICH Q3C for residual solvents, and 21 CFR 211.113 for microbiological control of water-based granulation steps. The terminal finished product types are single-dose granules for oral suspension, granule sticks for direct oral intake, or coated granules for delayed release if a functional polymer coating is applied; however, oxiracetam as an immediate-release cognitive API is generally supplied as uncoated sachet granules for reconstitution. A limitation is that direct delivery of pure active powder without granulation is unsuitable for sachet filling because the high active fraction above 80.0 wt% may lead to static adhesion and poor filling accuracy.

In lyophilized injectable manufacturing, oxiracetam is dissolved in Water for Injection and converted into a freeze-dried cake only after thermal stability data justify the removal of water; the process is chosen for presentations that must avoid terminal sterilization or when the solution is unstable in liquid form over the required shelf-life. A lyophilized vial containing 1.00 g of oxiracetam filled from a solution of 100 mg/mL uses a 10.0 mL fill volume per vial; this arithmetic ratio places the API in the final solution at 100 g/L before filtration. The bulk solution is compounded under nitrogen-poor or nitrogen-purged conditions only if process development shows oxidative degradation; oxiracetam is freely soluble in water, so cosolvents are not required at this concentration. The solution is passed through a sterilizing-grade 0.22 µm filter, and filter integrity testing is performed both before and after filling using the bubble-point or forward-flow method selected from ISO 13408-1 and supplier-specific filter data. The fill is carried out under EU GMP Annex 1 Grade A conditions with a Grade B background; the aseptic intervention protocol and environmental monitoring data must support the absence of contamination. The filled vials are partially stoppered and transferred to a freeze-drier; the cycle is developed using freeze-drying microscopy and thermal characterization of the formulation, with an annealing step introduced only if the API forms metastable glass domains that crack during primary drying. The residual moisture specification in the lyophilized cake is typically established between 0.5% and 2.0% based on stability data; compendial testing includes USP <71> sterility, USP <85> bacterial endotoxins with an endotoxin limit calculated from the maximum bolus dose in the prescribing information, USP <788> particulate matter in injections, USP <790> visible particulates, and ICH Q3D for elemental impurities. Packaging uses borosilicate Type I glass vials with bromobutyl rubber stoppers and aluminum flip-off seals; the closure system is verified for container closure integrity under USP <1207> or Ph. Eur. 3.2.9 stopper specifications. Terminal finished product types for this route are lyophilized powders for solution for injection, reconstituted before intravenous or intramuscular administration, and dual-chamber syringe configurations only where marketed presentations exist. A critical process boundary is that the lyophilization cycle must not be transposed from other racetam injections without reformulation-specific thermal data, because differences in cake morphology can alter reconstitution time and particulate levels; published data for this specific oxiracetam configuration is limited in peer-reviewed literature, so cycle design relies on formulation-specific freeze-drying studies.

When Sterile Ready-to-Fill Solutions Are Selected Over Lyophilized Vials

A ready-to-fill solution presentation is designated when the API remains chemically stable in aqueous solution at the proposed fill concentration for the marketed shelf-life and when terminal sterilization can be validated without unacceptable degradation. A 100 mg/mL oxiracetam solution in a 5 mL low-density polyethylene ampoule or Type I glass ampoule delivers 500 mg per unit; this places the API input at 100.0 g/L of final bulk solution before filtration. No chemical overage is added unless the marketing authorization explicitly permits a product-specific overage to offset possible filtration losses; any overage must be justified by filter binding and fill-line loss data, not by arbitrary process adjustment. The compounding tank is charged with Water for Injection at 20–25°C and the API is dissolved under controlled agitation; the solution is not pH-adjusted unless stability data demonstrate hydrolysis or precipitation, because unnecessary buffer ions can elevate tonicity and complicate osmotic pressure control. The bulk solution is sterile-filtered through a sterilizing-grade membrane, and then filled into ampoules or vials in a Grade A zone with Grade B background under EU GMP Annex 1. If terminal sterilization is selected, the filled sealed containers are autoclaved at 121°C for 15 min or an equivalent F₀ value based on the container size and load pattern; if terminal sterilization is not possible, the aseptic filtration process is used and the filter integrity test result becomes release-controlling. In-process checks include bioburden before filtration, solution clarity, osmolality if the label specifies isotonicity, and density for fill-weight conversion. Release testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, USP <790> visible particulates, ICH Q3C residual solvents, and ICH Q3D elemental impurities; container closure integrity is tested under USP <1207> with dye ingress or vacuum decay after capping. The terminal finished product types are aqueous injection solutions in ampoules or vials, single-dose units for intravenous infusion after dilution, or ready-to-administer pre-filled syringes where a licensed presentation exists. A major operational boundary is thermal stability: if forced-degradation studies show that the solution forms more than 0.10% total impurities at elevated temperatures, terminal sterilization is excluded and aseptic filtration becomes the only workable fill line. In that case, the filling line must be qualified for media-fill reproducibility and environmental monitoring; published data for terminal sterilization of oxiracetam solutions is limited, so product-specific thermal cycling is required before setting the sterilization decision.